The National Comprehensive Cancer Network (NCCN) treatment guidelines emphasize the significance of identifying the tissue of origin so that standard-of-care, cancer-specific treatment recommendations can be followed. In cases of tumors of uncertain origin, diagnostic workup using current methods is difficult, frustrating and often inconclusive. Patient management is challenging, expensive and fraught with uncertainty for physician and patient. The Pathwork® Tissue of Origin Test may reduce uncertainty, improve patient outcomes, and save money.
The Pathwork Tissue of Origin Test is designed to give you information on the tissue of origin for hard-to-identify tumor specimens, when an answer is not available using current methodologies. With this information, you may make treatment decisions with more confidence and eliminate one of the frustrating uncertainties for you and your patients.
- In a study of 487 metastatic and poorly differentiated and undifferentiated tumors already identified by current methodologies, the Pathwork Tissue of Origin Test demonstrated a sensitivity of 89 percent and a specificity of 99 percent. (Monzon FA, Lyons-Weiler M, Buturovic LJ, et al. Association for Molecular Pathology Annual Meeting, 2007, Abstract #ST02)
- In a cross-laboratory comparison study of 60 metastatic and poorly differentiated and undifferentiated tissue specimens, the test demonstrated an average 94 percent overall concordance across four laboratories. (CI Dumur, et al. J Mol Diagn. 2008;10:67-77)
The Pathwork Tissue of Origin Test is now available to oncologists and pathologists through the CLIA-certified Pathwork® Diagnostics Laboratory.
